| Thursday November 30, 2017 | ||||
 10:10 - 10:35 | Welcome Coffee | |||
| 10:35 - 11:35 | Satellite Symposium EXCEMED - Excellence in Medical Education Today's choices for tomorrow’s reality Introduction and welcome
Giancarlo Comi Immunological modes of action and clinical efficacy of emerging MS treatments Heinz Wiendl High efficacy treatments in the management of patients Klaus Schmierer Tackling clinical decision making and conclusions Gavin Giovannoni | |||
| 11:35 - 11:45 | Break | |||
| 11:45 - 12:45 | Industry-sponsored Satellite Symposium Merck Satellite Symposium
Welcome and objectives
Hans-Peter Hartung Cladribine Tablets: an innovative treatment that provides durable efficacy in MS Oscar Fernandez Cladribine Tablets: Safety and tolerability profile and implication for monitoring Antonio Uccelli Q&A - Panel discussion Wrap up and Close Hans-Peter Hartung | |||
| 12:45 - 13:15 | Light Lunch | |||
| 13:15 - 14:15 | XXV ECF Lecture Comi Giancarlo - Chair History of the Foundation and what has changed in these 25 years in Multiple Sclerosis
van Eikema Hommes Otto R.
| |||
| 14:15 - 16:00 | SESSION I: ABOUT THE CAUSES OF THE DISEASE Ebers George - Chair Lecture 1: Epidemiology Scalfari Antonio Lecture 2: Genetic Sawcer Stephen Lecture 3: Environmental factors Ascherio Alberto Lecture 4: Mucosal biopsy shows immunologic changes of the colon in patients with early MS Moser Adrian Mathias | |||
| 16:00 - 16:30 | Coffee Break and Poster Viewing | |||
| 16:30 - 18:00 | SESSION II: THE CHANGING LANDSCAPE OF BASIC STUDIES Freedman Mark - Chair Lecture 1: Pathology Brück Wolfgang Lecture 2: From a T cell story to a complex immune mechanism Wekerle Hartmut Lecture 3: Pathophysiological mechanism in the various phases of the disease Lassmann Hans Lecture 4: Intrathecal inflammatory profile and cortical damage can stratify MS patients Magliozzi Roberta | |||
| 18:00 - 18:15 | Coffee Break | |||
| 18:15 - 19:15 | Industry-sponsored Satellite Symposium Sanofi Genzyme Satellite Symposium
Evolving landscapes in MS research and clinical practice - From traditional to novel measures
Welcome and Introduction
Nicola De Stefano Novel clinical measures to assess MS-related parameters and treatment efficacy Ralf Linker New insights into patient-reported outcomes in MS Iris-Katharina Penner Q&A | |||
| 19:15 - 20:15 | Welcome Cocktail | |||
| Friday December 1, 2017 | ||||
| 08:30 - 10:15 | SESSION III: HOW THE MS FACE HAS CHANGED Fujihara Kazuo - Chair Lecture 1: Diagnostic criteria a never ending story Edan Gilles Lecture 2: Classification of disease courses Cohen Jeffrey Lecture 3: At the border of MS (NMOSD, ADEM, anti MOG) Palace Jacqueline Lecture 4: Distinguishing MOG antibody disease from childhood MS Hacohen Yael | |||
| 10:15 - 11:15 | Coffee Break and Poster Viewing | |||
| 11:15 - 13:00 | SESSION IV: HOW TO MONITOR DISEASE EVOLUTION AND TREATMENT Miller Ariel - Chair Lecture 1: Role of brain MRI Fazekas Franz Lecture 2: Role of spiral cord MRI Filippi Massimo Lecture 3: Body fluids Khalil Michael Lecture 4: Neurophysiological biomarkers included OCT and more Leocani Letizia | |||
| 13:00 - 14:00 | Lunch | |||
| 14:00 - 15:45 | SESSION V: CLINICAL TRIALS AND OUTCOME MEASURES Boyko Alexey - Chair Lecture 1: Clinical trial designs Kappos Ludwig Lecture 2: Outcome measures Hobart Jeremy Lecture 3: Patient reported outcomes Solari Alessandra Lecture 4: Clinical trials in pediatric MS Ghezzi Angelo | |||
| 15:45 - 16:15 | Coffee Break | |||
| 16:15 - 18:00 | SESSION VI: FROM NO TREATMENT TO A COMPLEX TREATMENT ARMAMENTARIUM Selmaj Krzysztof - Chair Lecture 1: The evolution of treatment for relapsing MS Hartung Hans-Peter Lecture 2: Do we really hit the phenomenon of progression with available treatment Montalban Xavier Lecture 3: Efficacy and effectiveness Trojano Maria Lecture 4: Risk minimization in MS treatment Uitdehaag Bernard M. J. | |||
| 18:00 - 18:15 | Coffee Break | |||
| 18:15 - 19:15 | Industry-sponsored Satellite Symposium Celgene Satellite Symposium
Welcome and Introductions
Maria Pia Amato Exploring the Underlying Mechanism of Disease Ludwig Kappos S1P Modulators and Phase 2 & 3 Trials Hans-Peter Hartung Meeting Close Maria Pia Amato | |||
| Saturday December 2, 2017 | ||||
| 07:15 - 07:30 | Light Breakfast | |||
| 07:30 - 08:30 | Satellite Symposium MS in the 21st Century Dawn Langdon
The digital healthcare revolution: A journey towards patient engagement Gavin Giovannoni Debate: Patient power – do the benefits always outweigh the risks? Gavin Giovannoni & David Yeandle Moderated by: Dawn Langdon
Talking the same language: Progress and challenges for joint communication in MS Peter Rieckmann & David Yeandle
Q&A
Dawn Langdon
Close Dawn Langdon | |||
| 08:30 - 10:15 | SESSION VII: ENHANCING RECOVERY AND SYMPTOMATIC TREATMENT Thompson Alan - Chair Lecture 1: Molecular mechanism to enhance recovery Lubetzki Catherine Lecture 2: Where we are with physical and mental exercise Kesselring Jürg Lecture 3: Symptomatic treatment Sorensen Per Soelberg Lecture 4: Regenerative approaches for demyelinating diseases Simons Mikael | |||
| 10:15 - 10:45 | Coffee Break | |||
| 10:45 - 12:00 | SESSION VIII: TRANSLATING SCIENCE INTO PATIENT MANAGEMENT Cristiano Edgardo - Chair Lecture 1: How MS care is changed in Europe Fernandez Oscar Lecture 2: Dealing with increasing economic constraints Giovannoni Gavin Lecture 3: Multistakeholder initiative Vermersch Patrick Lecture 4: MS center organization Comi Giancarlo | |||
| 12:00 - 12:30 | Young Investigator Awards | |||
| 12:30 - 13:00 | Closing Remarks | |||
| 13:00 - 14:00 | Lunch | |||
